NEU 0.08% $13.01 neuren pharmaceuticals limited

potential partner, page-4

  1. 521 Posts.
    lightbulb Created with Sketch. 1286
    I always had a suspicion that the advice of Leerink is a Treagus strategy as a smoke screen to mislead alliance already established in the project in 2013 the party.
    I have more than a suspicion I think the change of strategy with Neuren related engagements for new employees as Shaw takes place in more or less coincide with the failure of the Seaside study (sponsored by Roche) in FX declared in May 2013.
    in the same period (late April 2013) the NEU crazy market went from 2.9 cents to 4.8 cents and then force the leadership with water thrown on the fire by the leadership May 15, 2013.
    I am analyzing the reality of that time that perhaps fate coincides with the change of Neuren route for trial, the hiring of Shaw which then opens collaboration with Roche and failure and waiver by Seaside leaving Neuren free field NNZ-2566. for as I see Roche remains in the hands empty handed with Seaside and engages with Neuren.
    https://www.fraxa.org/seaside-stx209-arbaclofen/
    http://www.stocknessmonster.com/news-item?S=NEU&E=ASX&N=735487
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.